Sialidase NEU4 is involved in glioblastoma stem cell survival

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Silvestri, I ^a   Testa, F ^a   Zappasodi, R ^b   Cairo, C W ^c   Zhang, Y ^c   Lupo, B ^d   Galli, R ^e   Di Nicola, M ^b   Venerando, B ^a   Tringali, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ALBERTA   (Canada)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GANGLIOSIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN; GSK3B PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; LEUKOCYTE ANTIGEN; MICRORNA; NANOG PROTEIN, HUMAN; NEU4 PROTEIN, HUMAN; OCTAMER TRANSCRIPTION FACTOR 4; PEPTIDE; PROM1 PROTEIN, HUMAN; SHH PROTEIN, HUMAN; SIALIDASE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX;

ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL SURVIVAL; CYTOLOGY; GENE SILENCING; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

AC133 ANTIGEN; ANTIGENS, CD; CELL LINE, TUMOR; CELL SURVIVAL; GANGLIOSIDES; GENE SILENCING; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; GLYCOPROTEINS; HEDGEHOG PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; NANOG HOMEOBOX PROTEIN; NEOPLASTIC STEM CELLS; NEURAMINIDASE; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; SOXB1 TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84906880198     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.349     Document Type: Article

References (54)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-2710.
2. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011; 18: 66-70.
3. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
4. Akhtar K, Bussen W, Scott SP. Cancer stem cells - from initiation to elimination, how far have we reached? (Review). Int J Oncol 2009; 34: 1491-1503.
5. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-822.
6. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010; 80: 654-665.
7. Perez Castillo A, Aguilar-Morante D, Morales-Garcia JA, Dorado J. Cancer stem cells and brain tumors. Clin Transl Oncol 2008; 10: 262-267.
8. Kristoffersen K, Villingshoj M, Poulsen HS, Stockhausen MT. Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biol Ther 2013; 14: 625-637.
9. Bell D, Miele L. A magnifying glass on glioblastoma stem cell signaling pathways. Cancer Biol Ther 2011; 11: 765-768.
10. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010; 70: 719-729.
11. Lehnus KS, Donovan LK, Huang X, Zhao N, Warr TJ, Pilkington GJ et al. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. Int J Oncol 2013; 42: 1011-1017.
12. He J, Liu Y, Zhu TS, Xie X, Costello MA, Talsma CE et al. Glycoproteomic analysis of glioblastoma stem cell differentiation. J Proteome Res 2011; 10: 330-338.
13. Klassen H, Schwartz MR, Bailey AH, Young MJ. Surface markers expressed by multipotent human and mouse neural progenitor cells include tetraspanins and non-protein epitopes. Neurosci Lett 2001; 312: 180-182.
14. Yanagisawa M, Nakamura K, Taga T. Roles of lipid rafts in integrin-dependent adhesion and gp130 signalling pathway in mouse embryonic neural precursor cells. Genes Cells 2004; 9: 801-809.
15. Nakatani Y, Yanagisawa M, Suzuki Y, Yu RK. Characterization of GD3 ganglioside as a novel biomarker of mouse neural stem cells. Glycobiology 2010; 20: 78-86.
16. Wang J, Yu RK. Interaction of ganglioside GD3 with an EGF receptor sustains the selfrenewal ability of mouse neural stem cells in vitro. Proc Natl Acad Sci USA 2013; 110: 19137-19142.
17. Yanagisawa M. Stem cell glycolipids. Neurochem Res 2011; 36: 1623-1635.
18. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumorinitiating cells in human glioblastoma. Cell Stem Cell 2009; 4: 440-452.
19. Tringali C, Lupo B, Anastasia L, Papini N, Monti E, Bresciani R et al. Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling. J Biol Chem 2007; 282: 14364-14372.
20. Tringali C, Lupo B, Cirillo F, Papini N, Anastasia L, Lamorte G et al. Silencing of membraneassociated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3. Cell Death Differ 2009; 16: 164-174.
21. Tringali C, Lupo B, Silvestri I, Papini N, Anastasia L, Tettamanti G et al. The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling beta1 integrin internalization and recycling. J Biol Chem 2012; 287: 42835-42845.
22. Tringali C, Cirillo F, Lamorte G, Papini N, Anastasia L, Lupo B et al. NEU4L sialidase overexpression promotes beta-catenin signaling in neuroblastoma cells, enhancing stem-like malignant cell growth. Int J Cancer 2012; 131: 1768-1778.
23. Miyagi T, Wada T, Yamaguchi K, Shiozaki K, Sato I, Kakugawa Y et al. Human sialidase as a cancer marker. Proteomics 2008; 8: 3303-3311.
24. Monti E, Preti A, Venerando B, Borsani G. Recent development in mammalian sialidase molecular biology. Neurochem Res 2002; 27: 649-663.
25. Proshin S, Yamaguchi K, Wada T, Miyagi T. Modulation of neuritogenesis by gangliosidespecific sialidase (Neu 3) in human neuroblastoma NB-1 cells. Neurochem Res 2002; 27: 841-846.
26. Da Silva JS, Hasegawa T, Miyagi T, Dotti CG, Abad-Rodriguez J. Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat Neurosci 2005; 8: 606-615.
27. Kappagantula S, Andrews MR, Cheah M, Abad-Rodriguez J, Dotti CG, Fawcett JW. Neu3 sialidase-mediated ganglioside conversion is necessary for axon regeneration and is blocked in CNS axons. J Neurosci 2014; 34: 2477-2492.
28. Shiozaki K, Koseki K, Yamaguchi K, Shiozaki M, Narimatsu H, Miyagi T. Developmental change of sialidase neu4 expression in murine brain and its involvement in the regulation of neuronal cell differentiation. J Biol Chem 2009; 284: 21157-21164.
29. Itokazu Y, Yu RK. Amyloid beta-peptide 1-42 modulates the proliferation of mouse neural stem cells: upregulation of fucosyltransferase IX and notch signaling. Mol Neurobiol 2014; e-pub ahead of print 17 January 2014.
30. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
31. Price MA, Kalderon D. Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1. Cell 2002; 108: 823-835.
32. Jia J, Amanai K, Wang G, Tang J, Wang B, Jiang J. Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature 2002; 416: 548-552.
33. Ferkey DM, Kimelman D. GSK-3: new thoughts on an old enzyme. Dev Biol 2000; 225: 471-479.
34. Santoni M, Burattini L, Nabissi M, Morelli MB, Berardi R, Santoni G et al. Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci 2013; 14: 133-140.
35. Rossi M, Magnoni L, Miracco C, Mori E, Tosi P, Pirtoli L et al. Beta-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 2011; 11: 753-761.
36. Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 2013; 13: 51-65.
37. Albohy A, Zhang Y, Smutova V, Pshezhetsky AV, Cairo CW. Identification of selective nanomolar inhibitors of the human neuraminidase, NEU4. ACS Med Chem Lett 2013; 4: 532-537.
38. Finlay TM, Jayanth P, Amith SR, Gilmour A, Guzzo C, Gee K et al. Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9. Glycoconj J 2010; 27: 329-348.
39. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
40. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 2010; 70: 7500-7513.
41. Monti E, Bassi MT, Bresciani R, Civini S, Croci GL, Papini N et al. Molecular cloning and characterization of NEU4, the fourth member of the human sialidase gene family. Genomics 2004; 83: 445-453.
42. Bigi A, Tringali C, Forcella M, Mozzi A, Venerando B, Monti E et al. A proline-rich loop mediates specific functions of human sialidase NEU4 in SK-N-BE neuronal differentiation. Glycobiology 2013; 23: 1499-1509.
43. Korur S, Huber RM, Sivasankaran B, Petrich M, Morin Jr P, Hemmings BA et al. GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One 2009; 4: e7443.
44. Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001; 128: 5201-5212.
45. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17: 165-172.
46. Iida H, Suzuki M, Goitsuka R, Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 2012; 40: 71-79.
47. Yue X, Lan F, Yang W, Yang Y, Han L, Zhang A et al. Interruption of beta-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells. Brain Res 2010; 1366: 27-37.
48. Paul I, Bhattacharya S, Chatterjee A, Ghosh MK. Current understanding on EGFR and Wnt/beta-catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013; 4: 427-446.
49. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA 2013; 110: 6829-6834.
50. Furukawa K, Horie M, Okutomi K, Sugano S, Furukawa K. Isolation and functional analysis of the melanoma specific promoter region of human GD3 synthase gene. Biochim Biophys Acta 2003; 1627: 71-78.
51. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007; 67: 6121-6129.
52. Cheray M, Petit D, Forestier L, Karayan-Tapon L, Maftah A, Jauberteau MO et al. Glycosylation-related gene expression is linked to differentiation status in glioblastomas undifferentiated cells. Cancer Lett 2011; 312: 24-32.
53. Taniguchi A, Saito K, Kubota T, Matsumoto K. Characterization of the promoter region of the human Galbeta1,3(4)GlcNAc alpha2,3-sialyltransferase III (hST3Gal III) gene. Biochim Biophys Acta 2003; 1626: 92-96.
54. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003; 22: 1324-1332.